
NanoViricides NNVC
$ 1.15
-2.54%
NanoViricides Operating Cash Flow | NNVC
Annual Operating Cash Flow NanoViricides
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.7 M | -8.48 M | -6.32 M | -5.67 M | -5.89 M | -8.21 M | -6.67 M | -6.8 M | -7.78 M | -7.9 M | -6.83 M | - | - | -5.8 M | -4.22 M | -4.51 M | -2.05 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.05 M | -8.48 M | -6.32 M |
Quarterly Operating Cash Flow NanoViricides
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.64 M | -2.12 M | -1.93 M | -2.05 M | -1.59 M | -1.7 M | -1.99 M | -2.19 M | -2.59 M | -1.48 M | -1.94 M | -1.72 M | -1.17 M | -1.5 M | -1.74 M | -1.4 M | -1.03 M | - | -1.03 M | -2.43 M | - | - | -3.15 M | -2.11 M | -724 K | - | -2.4 M | -324 K | -2.24 M | - | -1.43 M | -2.16 M | -962 K | - | -962 K | -3.12 M | -962 K | - | -1.56 M | -2.96 M | -1.56 M | - | -2.22 M | - | - | - | - | - | - | - | - | - | - | - | -1.32 M | - | -27.3 M | -897 K | -1.42 M | -2.72 M | -1.35 M | - | -676 K | -1.9 M | -676 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -324 K | -27.3 M | -2.33 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Rigel Pharmaceuticals
RIGL
|
75.7 M | $ 40.05 | -2.78 % | $ 720 M | ||
|
Celsion Corporation
CLSN
|
-13.9 M | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
-35.8 M | $ 1.27 | -8.27 % | $ 49.8 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
3.63 B | $ 514.68 | -1.15 % | $ 132 B | ||
|
Genfit SA
GNFT
|
15.5 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-12.9 M | - | -13.47 % | $ 169 M | ||
|
SELLAS Life Sciences Group
SLS
|
-28.4 M | $ 13.67 | -8.01 % | $ 1.49 B | ||
|
CureVac N.V.
CVAC
|
102 M | - | - | $ 867 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | ||
|
Rezolute
RZLT
|
-64.6 M | $ 3.92 | -6.69 % | $ 407 M | ||
|
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-1.53 M | $ 0.63 | -7.05 % | $ 67.2 M | ||
|
MorphoSys AG
MOR
|
-296 M | - | 2.43 % | $ 254 M | ||
|
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-55.1 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M | ||
|
Seer
SEER
|
-44.4 M | $ 1.34 | -3.25 % | $ 74.5 M | ||
|
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | ||
|
Summit Therapeutics
SMMT
|
-323 M | $ 9.94 | -6.01 % | $ 7.43 B | ||
|
Shattuck Labs
STTK
|
-39.9 M | $ 4.49 | -1.43 % | $ 312 M | ||
|
Silence Therapeutics plc
SLN
|
-39.4 M | $ 19.81 | 0.08 % | $ 2.81 B | ||
|
Soligenix
SNGX
|
-10.3 M | $ 0.22 | -8.25 % | $ 1.14 M | ||
|
Sanofi
SNY
|
10.8 B | $ 46.51 | 0.97 % | $ 56.8 B | ||
|
Spruce Biosciences
SPRB
|
-33.3 M | $ 38.02 | -6.11 % | $ 29.1 M | ||
|
Spero Therapeutics
SPRO
|
-12.6 M | $ 0.74 | -10.95 % | $ 41.5 M | ||
|
Sarepta Therapeutics
SRPT
|
-205 M | $ 13.34 | -5.86 % | $ 1.34 B | ||
|
Savara
SVRA
|
-101 M | $ 4.28 | -17.95 % | $ 952 M | ||
|
Sutro Biopharma
STRO
|
-177 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Tarsus Pharmaceuticals
TARS
|
-12.5 M | $ 72.94 | -6.09 % | $ 3.05 B | ||
|
Supernus Pharmaceuticals
SUPN
|
47.3 M | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
-24.8 M | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Viridian Therapeutics
VRDN
|
-276 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Trevi Therapeutics
TRVI
|
-42.1 M | $ 13.35 | -2.73 % | $ 1.8 B | ||
|
vTv Therapeutics
VTVT
|
-25.3 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
-279 M | $ 36.89 | -1.78 % | $ 2.92 B | ||
|
Xeris Pharmaceuticals
XERS
|
28.6 M | $ 16.95 | 2.02 % | $ 2.72 B | ||
|
X4 Pharmaceuticals
XFOR
|
-85.6 M | $ 3.01 | 1.69 % | $ 127 M |